Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
SHERWIN WILLIAMS CO | Director | Common Stock | 11,869 | $3.94 M | $331.56 | Apr 5, 2024 | Direct |
REGENERON PHARMACEUTICALS, INC. | Director | Common Stock | 2,172 | $2.07 M | $951.26 | Jan 2, 2024 | Direct |
PRUDENTIAL FINANCIAL INC | Director | Notional Shares - Mandatory | 12,382 | $1.41 M | $113.97 | Jun 13, 2024 | Direct |
PRUDENTIAL FINANCIAL INC | Director | Common Stock | 11,583 | $1.37 M | $117.95 | May 9, 2024 | Direct |
SHERWIN WILLIAMS CO | Director | Common Stock | 2,471 | $819 K | $331.56 | Apr 5, 2024 | Deferred Fee Plan |
PRUDENTIAL FINANCIAL INC | Director | Notional Shares - Optional | 3,800 | $433 K | $113.97 | Jun 13, 2024 | Direct |
NEUROCRINE BIOSCIENCES INC | Director | Non-Qualified Stock Option | 2,982 | $219 K | $73.60 | May 22, 2024 | Direct |
NEUROCRINE BIOSCIENCES INC | Director | Restricted Stock Unit | 1,435 | $204 K | $141.90 | May 22, 2024 | Direct |
PRUDENTIAL FINANCIAL INC | Director | 2024 Restricted Stock Units | 1,276 | $145 K | $113.97 | Jun 13, 2024 | Direct |
PRUDENTIAL FINANCIAL INC | Director | 2023 Restricted Stock Units | 0 | $0 | $116.58 | May 9, 2024 | Direct |
REGENERON PHARMACEUTICALS, INC. | Director | Non-Qualified Stock Option (right to buy) | 1,607 | Jan 2, 2024 | Direct |